Indication: Respiratory Syncytial Virus (RSV)

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)

Sub-indication: Respiratory Syncytial Virus (RSV)

Drug Study

Principal Investigator: Gary Marshall, M.D.
Norton Children's Infectious Diseases, affiliated with the UofL School of Medicine

Sponsor: MedImmune, LLC

Search our entire site.